Biogen faces tough questions over $56K a year price of newly approved Alzheimer's drug

The company said is it charging $56,000 for an annual course of the treatment, higher than the $10,000 to $25,000 price some analysts were expecting.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.